-transparent.png){kind=logo}
In a randomized double-blind study with parallel group design involving 60 anxious psychoneurotic outpatients, the anxiolytic activity of alprazolam was compared with that of oxazepam. Following a 4 to 7-day placebo washout period, both groups showed a similar and significant response to treatment during the 4-week active treatment phase. An important intergroup difference emerged in the fear/anxiety component of the Lipman SRSS with the alprazolam groups showing a significantly greater mean reduction from the baseline score. During alprazolam treatment there was also a significant reduction in the depression factor score of the Lipman SRSS by the termination of the study and for all 4 weeks combined. Furthermore, the global impression of treatment was judged by patients as more favourable towards alprazolam than towards oxazepam. Only one person in each group reported a serious side effect. The results indicate that the anxiolytic activity of alprazolam is at least as good as that of oxazepam.
E Väisänen, and
E Jalkanen
February 1983,
The Journal of clinical psychiatry,
E Väisänen, and
E Jalkanen
May 1991,
Pharmacopsychiatry,
E Väisänen, and
E Jalkanen
December 1988,
Der Anaesthesist,
E Väisänen, and
E Jalkanen
January 1989,
Anaesthesiologie und Reanimation,
E Väisänen, and
E Jalkanen
January 1982,
Psychopharmacology,
E Väisänen, and
E Jalkanen
January 1987,
Pharmatherapeutica,
E Väisänen, and
E Jalkanen
January 1988,
Minerva psichiatrica,
E Väisänen, and
E Jalkanen
October 2001,
Journal of clinical pharmacy and therapeutics,
E Väisänen, and
E Jalkanen
March 1992,
Alcohol and alcoholism (Oxford, Oxfordshire),
E Väisänen, and
E Jalkanen
October 1994,
Journal of clinical psychopharmacology,
